Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

E1A RNA transcripts amplify adenovirus-mediated tumor reduction

L D Dion1, K T Goldsmith, T V Strong

  • 1Department of Medicine, UAB School of Medicine, Birmingham, AL, USA.

Gene Therapy
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inpatient hospitalisations for patients with Prader-Willi syndrome: a 2019-2021 National Inpatient Sample analysis.

Journal of intellectual disability research : JIDR·2024
Same author

Long-term impact of subthalamic stimulation on cognitive function in patients with advanced Parkinson's disease.

Neurologia·2017
Same author

Molecular and antigenic characterization of bovine Coronavirus circulating in Argentinean cattle during 1994-2010.

Veterinary microbiology·2015
Same author

Augmented adenovirus transduction of murine T lymphocytes utilizing a bi-specific protein targeting murine interleukin 2 receptor.

Cancer gene therapy·2015
Same author

Gene therapy for radioprotection.

Cancer gene therapy·2015
Same author

Therapeutic adenoviral gene transfer of a glycosyltransferase for prevention of peritoneal dissemination and metastasis of gastric cancer.

Cancer gene therapy·2014
Same journal

Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters.

Gene therapy·2026
Same journal

Recent advancements in improving cross-species applicability of bioengineered AAV capsids.

Gene therapy·2026
Same journal

Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice.

Gene therapy·2026
Same journal

Applications of genome editing technologies in the treatment of human diseases.

Gene therapy·2026
Same journal

High resolution ES-DMA quantifies AAV capsid DNA content by electrical mobility to mass correlation.

Gene therapy·2026
Same journal

AAV8-mediated mouse/human PROC expression rescues thrombophilia in hereditary protein C-deficient mice.

Gene therapy·2026
See all related articles

Researchers developed a novel method to enable replication of E1-defective adenoviruses using RNA. This approach enhances adenovirus-mediated therapeutic effects in human tumors, showing promise for gene therapy applications.

Area of Science:

  • * Molecular Biology
  • * Gene Therapy
  • * Virology

Background:

  • * Previous work established the conditional replication-enablement system for adenovirus (CRESA) using plasmids for E1-defective adenoviruses.
  • * The CRESA strategy enables adenovirus replication by providing deleted E1 functions via codelivery of a plasmid.

Purpose of the Study:

  • * To investigate replacing the E1-encoding plasmid in CRESA with separate plasmids for E1A and E1B functions.
  • * To evaluate the functional substitution of an E1A plasmid with an RNA transcript encoding E1A functions.
  • * To assess the impact of this modified CRESA system on adenovirus replication and therapeutic efficacy in vivo.

Main Methods:

  • * Adenovirus replication was studied in vitro using E1-defective adenoviruses with codelivered plasmids encoding E1A and E1B functions.

Related Experiment Videos

  • * An RNA transcript encoding E1A functions was tested as a substitute for the E1A plasmid.
  • * Therapeutic efficacy was evaluated in subcutaneous human tumor models using an adenovirus expressing herpes simplex virus thymidine kinase (HSVtk).

    • Main Results:

    • * An RNA transcript functionally substituted for the E1A plasmid without significantly reducing adenovirus production in vitro.
    • * No replication-competent adenovirus was detected in cells treated with the RNA and plasmid combinations.
    • * Adenovirus-mediated therapeutic effects, measured by tumor nodule reduction, were augmented when using the RNA + DNA-based replication-enablement system.

    Conclusions:

    • * E1-defective adenoviruses can be conditionally replication-enabled using an RNA transcript encoding required E1 functions.
    • * This RNA-based replication-enablement strategy is sufficient to enhance adenovirus-mediated therapeutic effects in vivo.
    • * The findings present a refined CRESA system with potential for improved gene therapy applications.